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the impact of trimetazidine on 
Disease Severity and Quality of Life 
in parkinson’s Disease
Dávid pintér1 ✉, Annamária Juhász1, Márk Harmat1, József Janszky1,2 & norbert Kovács1,2
trimetazidine is contraindicated in movement disorders, however, a not negligible part of trimetazidine 
users is still patients with parkinson’s disease (pD). the present study aimed to objectively determine 
the impact of trimetazidine on the severity of symptoms and the health-related quality of life of 
patients with PD by measuring changes after its withdrawal. A consecutive series of 42 patients with 
pD using trimetazidine underwent detailed neurological and neuropsychological assessments at 
baseline and three months after the discontinuation of trimetazidine. clinically relevant improvements 
were achieved with discontinuation of trimetazidine according to changes in scores of each part of 
the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (Part I: −25.7%, 
p < 0.001; Part II: −23.8%, p < 0.001; Part III: −28.5%, p < 0.001; Part IV: −30.1%, p = 0.004) and 
total scores of the non-Motor Symptoms Scale (−25.6%, p = 0.004) and the Montgomery-Asberg-
Depression Rating Scale (−20.1%, p = 0.001). Benefits resulting from the withdrawal of the drug also 
manifested in the improvement of the health-related quality of life based on changes in the summary 
index of the 39-item Parkinson’s Disease Questionnaire (−18.2%, p = 0.031). Our results provide clinical 
rationale for strictly avoiding the use of trimetazidine in pD. Discontinuation of trimetazidin results in 
clinically relevant improvements in parkinsonian symptoms.
Antipsychotics are the best known causes of drug-induced parkinsonism and medication-related symptom dete-
rioration of patients with Parkinson’s disease (PD)1. However, it is a frequently forgotten fact that a number of 
other commonly used medications, such as antiemetics (e.g., metoclopramide), drugs for preventive migraine 
therapy (e.g., flunarizine, and cinnarizine), antiepileptic (e.g., valproate) and antianginal drugs (e.g., trimetazi-
dine), may also be responsible for drug-induced movement disorders and worsening of Parkinsonian symptoms2.
Trimetazidine (1-[2,3,4-trimethoxibenzyl]-piperazine, TMZ) is a widely used add-on therapy for the symp-
tomatic treatment of stable coronary heart disease3–5. In addition to some rare side effects associated with TMZ 
treatment, including nausea, vomiting, epigastric pain, headache, liver dysfunction, thrombocytopenia, and 
agranulocytosis6,7; ample evidence exists for adverse effects of the drug on motor function. TMZ can induce 
reversible parkinsonism, tremor, and orofacial dyskinesia5,7–13; and aggravate symptoms of existing movement 
disorders including PD5,7. These effects of the drug might result from its piperazine core10, which can also be 
found in prochlorperazine and fluphenazine, antipsychotics reported to induce parkinsonism and worsen PD1,14. 
Drugs owning a piperazine core can process strong postsynaptic inhibition of dopamine receptors, including 
dopamine D2 receptors10, which are present in many brain structures such as the striatum having a substantial 
role in regulation of movements. The potential antipsychotic-like effect of TMZ described in a rodent model may 
also support the hypothesis that TMZ can cross the blood-brain barrier and interact with dopamine receptors in 
the central nervous system15.
Based on available findings, the European Medicines Agency (EMA) made a recommendation for the more 
careful use of TMZ in certain groups of patients and against the application of the drug for the treatment of 
patients with PD in 201216. However, some recent data show that this recommendation is not followed strictly 
enough since a not negligible part of TMZ users is still patients with movement disorders diagnosed prior to the 
prescription of the drug13.
Although motor symptoms of reversible TMZ-induced parkinsonism have been considered to be mild 
by previous descriptions5,7,9,11, they can have a serious impact on the health-related quality of life (HRQoL)5. 
However, parkinsonism induced or aggravated by TMZ treatment is also characterized by a sustained complete 
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symptomatic remission or improvement after the discontinuation of the drug;5,8,9,11 therefore, withdrawal of TMZ 
may theoretically improve the HRQoL of patients both with reversible parkinsonism and PD aggravated by the 
drug.
This single-center, prospective, longitudinal study aimed to objectively evaluate the impact of TMZ treatment 
on the severity of Parkinsonian symptoms and the HRQoL of subjects with PD. We tried to explore the effects of 
discontinuation of TMZ.
Materials and Methods
Study population and protocol. All study-related procedures were approved by the Regional and 
Institutional Ethical Committee (3617.316-24987/KK41) and performed in accordance with the Declaration of 
Helsinki.
The present study included a consecutive series of 42 patients with the clinical diagnosis of PD based on the 
UK Brain Bank criteria17,18 and concomitant TMZ treatment who presented at the Department of Neurology, 
University of Pécs, Hungary between 2014 and 2018. TMZ treatment (initiation of the drug in subjects with 
previously established PD or ongoing TMZ treatment after the diagnosis of PD) had been applied independently 
of the authors. The University of Pécs is a tertiary movement disorders center, and many of the participants were 
referred for further treatment. Each patient was examined immediately after learning the concomitant use of 
TMZ (baseline examination, BL).
After obtaining an individual written informed consent for participating in the study, all enrolled patients 
underwent detailed neurological and neuropsychological assessments at BL. None of the enrolled subjects was 
treated with other medications (e.g., antipsychotics, calcium channel blockers, and antiemetics) which could have 
worsened the symptoms of PD. Subsequently, TMZ treatment was discontinued, and patients were reevaluated 3 
months after the withdrawal of the drug (follow-up, FU) based on the recommendation given by the EMA16. Oral 
antiparkinsonian treatment remained stable in all subjects in the interval between the BL and 3-month FU visits. 
The included patients were followed for at least a 12-month period after the withdrawal of TMZ.
Assessed scales. In addition to demographic data (e.g., age, sex, and level of education), disease-specific data 
(e.g., duration of disease defined as the interval between the first observed PD-related motor problems and the 
time of BL examinations) and type of PD (tremor dominant, rigid-akinetic or mixed type), the severity of disease 
was globally measured by the Hungarian validated version of the Movement Disorders Society-sponsored Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS)19,20. Based on Part III of the MDS-UPDRS, an axial score (pos-
tural instability and gait difficulty, PIGD) was calculated21. The nested version of the Hoehn-Yahr Scale (HYS), 
which is included in the MDS-UPDRS, was also obtained; and the patients were categorized based on the overall 
disease severity as mild (HYS 1&2), moderate (HYS 3) and severe (HYS 4&5)22.
For the better characterization of nonmotor symptoms of the study population, the Hungarian validated 
versions of the Non-Motor Symptoms Scale (NMSS)23, the Montgomery-Asberg Depression Rating Scale 
(MADRS)24, the Parkinson’s Disease Sleep Scale 2nd version25, and the Epworth Sleepiness Scale26 were used. 
Cognitive performance was measured by the Hungarian validated versions (7.1, 7.2 and 7.3) of the Montreal 
Cognitive Assessment27.
To measure the HRQoL, the Hungarian validated version of the 39-item Parkinson’s Disease Questionnaire 
(PDQ-39)28 was applied.
All the scales were assessed both during the BL and the FU visits.
Statistical analysis. To test normality, the Shapiro-Wilk test was used. Because most of the data from the 
applied scales followed the normal distribution, mean and standard deviation values were calculated. For the 
analysis of changes in scores of scales due to TMZ withdrawal, the paired samples t-test and the Wilcoxon signed 
rank test were utilized. For categorical variables (e.g., HYS), the Chi-square test was applied. The level of statistical 
significance was set at 0.05. All statistical analyses were performed using the IBM SPSS software package (version 
24.0.2, IBM Inc., Armonk, NY, USA).
Results
Sociodemographic and disease-specific data of the study population at BL are demonstrated in Table 1.
The mean duration of TMZ use, defined as the interval between initiation of TMZ and the BL visit, was 
78.5 ± 24.9 months. The mean daily administered dose of the drug at BL was 72.1 ± 9.8 mg.
Changes in the severity of motor and nonmotor symptoms of PD and the level of the HRQoL due to discon-
tinuation of TMZ are presented in Table 2. There were significant decreases of 4.0, 3.5, 10.4 and 1.2 points in 
Parts I, II, III and IV of the MDS-UPDRS, respectively. Change in the PIGD score (3.1 points) indicated a notable 
improvement in the severity of axial symptoms, including disturbances of posture, gait problems, and postural 
instability. Among others, the improvement of axial symptoms led to a significant reduction in HYS. None of the 
patients suffered from reversible parkinsonism, however, antiparkinsonian treatment led to complete disappear-
ance of motor symptoms (HYS 0) in two patients after the discontinuation of TMZ. In these two cases, discontin-
uation of antiparkinsonian medications resulted in the reemergence of Parkinsonian symptoms.
Most of the nonmotor symptoms also showed improvement, especially sleep problems and depression accord-
ing to changes in the sleep domain of the NMSS (−4.1 points) and the total score of the MADRS (−3.0 points). In 
addition to symptomatic improvement, there was a significant rise in the HRQoL indicated by the change in the 
summary index of the PDQ-39 (−3.8 points).
Discontinuation of TMZ and modification of antianginal treatment did not lead to any cardiovascular events 
(e.g., acute ischaemic coronary syndrome, refractory angina pectoris) in the included patients during a 12-month 
FU.
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Discussion
Pharmacotherapy requires caution in patients with PD because a number of medications can worsen the symp-
toms of the disease. Harmful effects of inadequate use of antipsychotics in PD1, including increased mortality29, 
are well-documented; however, some other medication-related causes of worsening of PD have been less studied. 
Analyzing data of patients who were treated with TMZ despite a previously established clinical diagnosis of PD, 
the present study evaluated the effects of TMZ on the severity of symptoms of PD and the HRQoL by objectively 
determining the level of improvement after discontinuation of the drug.
According to changes in scores of the MDS-UPDRS, not only the severity of motor symptoms improved 
(Part III) but also the disability caused by both motor and nonmotor symptoms of PD moderated (Parts I and II) 
after the discontinuation of TMZ. These changes were not just statistically significant but also clinically relevant 
considering the minimal clinically important difference (MCID) threshold values for each part of the scale (2.64, 
3.05, 3.25 and 0.9 points for improvement on Parts I, II, III and IV, respectively)30–32. Benefits of discontinuation 
of TMZ also manifested in a remarkable improvement of axial symptoms, which may indicate that TMZ worsens 
predominantly PIGD symptoms in patients with PD similarly to cases with reversible parkinsonism induced 
by the drug5. Axial symptoms are among the main sources of disability in PD and they can increase the risk of 
falls which can lead to additional problems including fractures and other injuries33, anxiety, depression, social 
isolation, and reduction of mobility34. Therefore, one of the main benefits of withdrawing TMZ in PD can be the 
improvement of the aforementioned problems.
The total score of the NMSS also detected a significant improvement in nonmotor symptoms. Of them, depres-
sion improved in a clinically relevant manner based on analysis of changes in total scores of the MADRS and con-
sidering the previously described MCID threshold value for this scale (from 1.6 to 1.9 points)35. Consequently, 
the use of TMZ in patients with PD and the negative impact of the drug on the severity of Parkinsonian symptoms 
seem to be clinically meaningful problems.
Current clinical research places a great emphasis on the exploration of the effects of disorders and thera-
peutic interventions on the HRQoL. Therefore, to measure the impact of TMZ on the HRQoL of patients with 
PD, changes in scores of the PDQ-39 due to the withdrawal of the drug were analyzed. Change in the summary 
index of the PDQ-39 indicated a statistically significant improvement in the global HRQoL. In addition, a sub-
stantial gain could be detected in the mobility domain of the PDQ-39. This may indicate that TMZ worsens 
predominantly bradykinesia, rigidity, and gait in patients with PD which is similar to the findings described in 
subjects with reversible TMZ-induced parkinsonism5. However, the change found by the present study did not 
exceed the MCID threshold for improvement established for the summary index of the PDQ-39 (4.72 points)28. 
A possible underlying cause for this ambiguous finding might be the relatively low number of included patients. 
Consequently, TMZ seems to have a negative impact on the HRQoL of patients with PD; however, further studies 
are warranted to clarify the clinical relevance of this phenomenon.
At present, a 24.5% improvement in the motor part of the MDS-UPDRS is considered to be a clinically rel-
evant response to levodopa during an acute levodopa challenge36. Improvement in the severity of Parkinsonian 
motor symptoms achieved in the present study with the discontinuation of TMZ alone (28.5%) exceeded this 
threshold. Bilateral subthalamic deep brain stimulation, an established and highly effective treatment option for 
advanced PD, has been reported to improve the summary index of the PDQ-39 by 28% during the first 6 months 
of stimulation37. Compared to deep brain stimulation, withdrawal of TMZ led to a lower level of, however, a not 
negligible improvement (18.2%) in the global HRQoL in the present study. These findings also indicate the seri-
ous impact of TMZ on the severity of PD and the HRQoL and support the clinical importance of avoiding the use 
of TMZ in PD or the withdrawal of the drug in PD patients who are treated with it.
Some recent data and the present study show that the use of TMZ in patients with movement disorders is still 
an unsolved problem. According to the results of a recent population-based study, 2.5% of TMZ users are still 
patients with preexisting movement disorders13. The present study analyzed data of 42 patients with PD from the 
prospective database of the Movement Disorders Unit at the University of Pécs including data of 1800+ patients. 
Characteristic
Mean ± standard 
deviation or n (%)
Age (years) 71.1 ± 8.1
Males 23 (54.8)
Right handed subjects 41 (97.6)
Education (years) 11.0 ± 3.0
Duration of disease (years) 3.3 ± 3.8
Duration of levodopa use (years) 3.0 ± 4.3
Levodopa LED (mg) 291.7 ± 468.2
Dopamine agonist LED (mg) 99.0 ± 227.1
Total LED (mg) 411.0 ± 582.4
Severity of disease
Mild (HYS 1&2) 25 (59.5)
Moderate (HYS 3) 9 (21.4)
Severe (HYS 4&5) 8 (19.1)
Table 1. Baseline characteristics for the study cohort (n = 42). Abbreviations: HYS = Hoehn-Yahr Scale; 
LED = levodopa equivalent dosage.
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Accordingly, approximately 2.3% of patients treated in our center were TMZ users prior to the study. However, 
such data may vary between centers and countries; therefore, studies involving analysis of data of a larger number 
of movent disorders centers and National Health Insurance databases of different countries are warranted for 
having a more reliable picture of the current clinical practice with TMZ.
Our results should be interpreted with caution since the study may have some limitations. First, we included 
patients representing a wide range of disease severity, however, a relatively low number of patients with moderate 
Baseline 
[mean ± SD or 
n (%)]
Follow-upa 
[mean ± SD or n 
(%)]
Change





MDS-UPDRS Part I 15.0 ± 7.1 10.9 ± 6.6 −4.0 ± 4.4 −25.7 <0.001
MDS-UPDRS Part II 13.1 ± 8.4 9.6 ± 6.9 −3.5 ± 4.7 −23.8 <0.001
MDS-UPDRS Part III 38.2 ± 14.4 27.8 ± 13.5 −10.4 ± 6.7 −28.5 <0.001
MDS-UPDRS Part IV 3.4 ± 3.2 2.2 ± 2.4 −1.2 ± 2.6 −30.1 0.004c
PIGD score 10.6 ± 6.2 7.5 ± 5.2 −3.1 ± 3.2 −27.9 <0.001
HYS
0 0 (0.0) 2 (4.8)
0.008d
1 1 (2.4) 3 (7.1)
2 24 (57.1) 28 (66.7)
3 9 (21.4) 4 (9.5)
4 7 (16.7) 5 (11.9)
5 1 (2.4) 0 (0.0)
Change in HYS after 
TMZ discontinuation
Improvement 16 (38.1)
No change 23 (54.8)
Worsening 3 (7.1)
NMSS
  Cardiovascular problems 3.5 ± 3.7 2.4 ± 3.2 −1.1 ± 3.7 −28.6 0.053c
  Sleep problems 14.3 ± 8.9 10.1 ± 7.3 −4.1 ± 7.3 −24.7 0.001
  Mood problems 14.7 ± 17.0 11.4 ± 13.4 −3.3 ± 13.5 −19.7 0.119
  Hallucinations 1.7 ± 3.9 1.8 ± 5.3 0.1 ± 5.3 5.1 0.931
  Memory problems 6.7 ± 7.7 4.8 ± 5.9 −1.9 ± 6.9 −23.6 0.085
  Gastrointestinal problems 5.5 ± 8.0 3.1 ± 5.2 −2.4 ± 6.7 −39.1 0.024
  Urinary problems 12.2 ± 10.0 9.6 ± 8.7 −2.5 ± 8.5 −20.5 0.060
  Sexual problems 0.9 ± 3.9 0.2 ± 0.5 −0.7 ± 3.9 −76.0 0.261c
  Miscellaneous 3.4 ± 5.0 3.3 ± 4.6 −0.2 ± 4.0 −5.8 0.790c
  Total 62.8 ± 49.9 46.6 ± 35.3 −16.2 ± 34.6 −25.6 0.004
MADRS 14.3 ± 8.8 11.4 ± 6.4 −3.0 ± 5.4 −20.1 0.001
PDSS-2 17.5 ± 10.9 15.1 ± 11.4 −2.4 ± 8.3 −13.8 0.068
ESS 6.4 ± 4.7 5.5 ± 4.7 −0.9 ± 5.0 −9.3 0.246
MoCA 22.2 ± 4.0 22.9 ± 4.0 0.5 ± 2.8 1.7 0.374
PDQ-39
  Mobility 30.2 ± 29.5 24.3 ± 23.6 −6.2 ± 18.9 −20.7 0.043
  Activities of daily living 20.7 ± 23.7 15.2 ± 16.4 −5.7 ± 19.3 −27.2 0.067
  Stigma 18.3 ± 27.3 13.1 ± 24.0 −5.6 ± 16.5 −26.2 0.034
  Emotional well-being 25.5 ± 18.5 25.3 ± 18.0 −0.2 ± 13.0 −0.4 0.920
  Social support 11.1 ± 14.0 6.9 ± 10.0 −4.5 ± 13.9 −37.2 0.046
  Cognition 19.6 ± 16.3 19.1 ± 13.4 −0.8 ± 12.1 −3.7 0.692
  Communication 14.7 ± 22.5 12.6 ± 21.3 −2.4 ± 17.9 −15.1 0.388
  Bodily discomfort 36.3 ± 24.1 31.1 ± 23.0 −5.3 ± 22.1 −11.1 0.134
  Summary index 21.9 ± 16.5 18.3 ± 13.9 −3.8 ± 10.8 −18.2 0.031
Table 2. Changes in scores of the applied scales due to discontinuation of trimetazidine. aFollow-up 
examinations were performed 95 ± 25 days after the baseline visit. bTo calculate relative change the following 
formula was used: (ScoreBaseline-ScoreFollow-up)/ScoreBaseline*100. cThe Wilcoxon signed rank test was used for 
the analysis of changes in these scores. dThe Chi-square test was utilized for the calculation of this value. 
Abbreviations: ESS = Epworth Sleepiness Scale; EQ = EuroQoL instrument; HYS = Hoehn-Yahr Scale; 
MADRS = Montgomery-Asberg Depression Rating Scale; MDS-UPDRS = Movement Disorder Society-
sponsored Unified Parkinson’s Disease Rating Scale; MoCA = Montreal Cognitive Assessment; NMSS = Non-
Motor Symptoms Scale; PDSS-2 = Parkinson’s Disease Sleep Scale 2nd version; PDQ-39 = 39-item Parkinson’s 
Disease Questionnaire; PIGD = postural instability and gait difficulty; TMZ = trimetazidine; VAS = visual 
analogue scale.
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and severe PD was evaluated. Additionally, only patients treated with oral antiparkinsonian medications were 
enrolled, therefore, some interactions between TMZ and PD treated with device-aided therapy might have 
remained unexplored. Furthermore, the results of this single-center study might have been influenced by factors 
related specifically to the institution and/or the country.
To conclude, our results provide clinical rationale for avoiding the use of TMZ in PD. TMZ seems to worsen 
the severity of Parkinsonian symptoms in a clinically meaningful manner and have a negative impact on the 
HRQoL. Therefore, discontinuation of the drug in patients with PD seems to be a clinically adequate therapeutic 
intervention; however, prevention should have priority. Although TMZ is contraindicated for the treatment of 
patients with PD, in line with some recent data, the present study suggests that the number of PD subjects with 
TMZ use is still not negligible. However, larger scale studies should also evaluate the prevalence of TMZ prescrip-
tions in patients with movement disorders, which could represent a more reliable picture of where we stand with 
the resolution of this still existing and clinically relevant problem.
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